Real World Evidence Solutions Market - Global Forecast to 2027





SPER Market Research

Real World Evidence Solutions Market - Global Forecast to 2027


Real World Evidence Solutions Market - Global Forecast to 2027

 Category : Medical Devices

 Published: Oct-2021
 Author: SPER Analyst
RWE Solutions Market is projected to be worth $2.48 Billion by 2027

The global RWE solutions market is expected to grow at a CAGR of ~13.5% from 2021 to reach ~2.48 billion by 2027. The growth of this market is primarily attributed to growing geriatric population, prevalence of chronic diseases, emphasis on value-based healthcare, increasing R&D investments, regulatory support and slow-paced drug development. However, growth can be hindered by factors such as lack of methodological standards and less trust real world studies. Rising focus on end-to-end real-world services provide with growth opportunities. 

Browse report overview on "Global RWE Solutions Market" at:

The global RWE solutions market study provides market data for-by component (services, data sets, clinical setting data, claims data, pharmacy data and patient powered data), by therapeutic area (oncology, cardiovascular, neurology, immunology and others), by end user (pharmaceutical & medical devices companies, healthcare providers, healthcare payers and other end users). The study also evaluates industry competitors and analyses the market at a regional and country level.

By component, services segment accounted for largest share of RWE solutions market in 2020. The large share is mainly attributed to growing concern to pace up the drug development process, need for evidence from data and availability of huge healthcare data.

By therapeutic area, oncology segment accounted for the largest market share in 2020. The large share of this segment is mainly due to increasing number of clinical trials and growing prevalence of cancer across globe. 

By end users, pharmaceutical & medical device companies segment dominated the RWE solutions market in 2020. The large share of this segment is mainly attributed to significance of RWE studies in drug approval process, growing need to prevent drug recalls and usefulness of drug performance data in real-world setting.

Don’t miss out on business opportunities in the "Global RWE Solutions Market". Request customized report as per your need and gain crucial industry insights that will help your business grow at:

This research report analyses major geographies and provides a comprehensive analysis of North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, India, Japan, and RoAPAC), Rest of the world (Latin America, and Middle East & Africa). North America commanded largest market share of RWE solutions market, by region. The largest share is attributed to regulatory support, growing number of payers, increasing RWE service providers and growing adoption of RWE by pharmaceutical companies in North America region. APAC is expected to exhibit highest CAGR in the forecast period. The growth of this regional market is mainly driven by government initiatives, prevalence of chronic diseases, increasing geriatric population and emphasis on improving healthcare services. 

The major players operating in the RWE solutions market are 
  • IQVIA (US)
  • IBM (US)
  • ICON plc. (Ireland)
  • PAREXEL International Corporation (US)
  • PPD, LLC (US)
  • Optum Inc. (US)
  • Cognizant (US)
  • Oracle (US)
  • SAS (US)
  • Syneos (US)
  • Anthem (US)
  • Clinigen (UK)
  • PerkinElmer (US)
  • Cerner Corporation (US)
  • Medpace (US)
  • Aetion (US)
  • Cegedim Health Data (France)
  • TriNetX (US)
  • Trinity (US)
  • Verantos (US)
  • Sciformix (US)
  • Ciox Health (US)
  • Tempus (US)
  • Flatiron Health (US)
  • And Syapse (US) 

Join SPER Panel


Market Research

We are the leading, full-service global market research and consulting company.

Secure Payments
SPER Payment Options
Connect with us